Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older.
- People whose overall health allows them to complete a full course of pelvic radiation therapy, with or without chemotherapy or internal radiation (brachytherapy).
- People who are able to understand the study information and are willing to sign a consent form.
- People who are willing to have extra tissue biopsies and blood samples taken for research purposes.
Cohort A (one of three groups):
- People diagnosed with locally advanced cervical cancer at a specific stage range (Stage IB2 to IIIC1, using the FIGO 2018 staging system) who are planned for curative treatment, or those at Stage IIIB to IVA where radiation for symptom relief is the planned approach.
- People who have not previously had radiation to the pelvis or chemotherapy.
Cohort B (one of three groups):
- People diagnosed with locally advanced cervical cancer at Stage IIIC2, using the FIGO 2018 staging system.
- People who have not previously had radiation to the pelvis or chemotherapy.
Cohort C (one of three groups):
- People diagnosed with a gynaecological cancer who need radiation directed at a specific area that has already been treated with radiation before (re-irradiation).
Who may not be able to join:
- People with a serious medical condition that would prevent them from completing the full treatment.
- People with a weakened immune system or a currently active infection.
- People currently taking medications that suppress the immune system for another medical condition.
- People who are planned to receive a type of cancer treatment known as immune checkpoint inhibitor therapy.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +022-68735000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To investigate the systemic immune response in patients undergoing radiotherapy for cervical cancer.; To study the multi-time point interaction between radiotherapy for cervical cancer and impact on tumor infiltrating immune cells and PD-L1 expression.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.